Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015 Feb;6(1):311-315.
doi: 10.14740/wjon866w. Epub 2015 Feb 14.

Overview of Recent Trends in the Management of Metastatic Anal Cancer

Mahender Yellu  1 , Ayham Deeb  2 , Olugbenga Olowokure  2
Affiliations
Case Reports

Overview of Recent Trends in the Management of Metastatic Anal Cancer

Mahender Yellu et al. World J Oncol. 2015 Feb.

Abstract

Anal cancer is a relatively rare gastrointestinal tumor with roughly 7,000 new cases per year. Metastatic anal cancer as an initial presentation occurs in 10-20% of the patients. Treatment for localized disease is well established with concurrent chemoradiation (CCR) therapy as the standard of care; however, metastatic anal cancer remains a therapeutic challenge. National Comprehensive Cancer Network (NCCN) guidelines recommend systemic chemotherapy as the initial choice of treatment for metastatic anal disease. NCCN also recognizes the fact that there are limited data to influence the management of metastatic anal cancer but that some evidence suggests flouropyrimidine and cisplatin as the initial choice of treatment outside the setting of clinical trial. If the patient fails this regimen, options become limited with no strong level I evidence available to guide the treatment. We present two cases of metastatic anal cancer and discuss the potential treatment strategies after failing the initial systemic chemotherapy.

Keywords: Chemotherapy; Management; Metastatic anal cancer; Radiotherapy.

PubMed Disclaimer

Conflict of interest statement

None to declare.

References

    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi: 10.3322/caac.21208. - DOI - PubMed
    1. Klas JV, Rothenberger DA, Wong WD, Madoff RD. Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. Cancer. 1999;85(8):1686–1693. doi: 10.1002/(SICI)1097-0142(19990415)85:8<1686::AID-CNCR7>3.0.CO;2-7. - DOI - PubMed
    1. Penn I. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer. 1986;58(3):611–616. doi: 10.1002/1097-0142(19860801)58:3<611::AID-CNCR2820580303>3.0.CO;2-M. - DOI - PubMed
    1. Sillman FH, Sedlis A. Anogenital papillomavirus infection and neoplasia in immunodeficient women: an update. Dermatol Clin. 1991;9(2):353–369. - PubMed
    1. Schlienger M, Krzisch C, Pene F, Marin JL, Gindrey-Vie B, Mauban S, Barthelemy N. et al. Epidermoid carcinoma of the anal canal treatment results and prognostic variables in a series of 242 cases. Int J Radiat Oncol Biol Phys. 1989;17(6):1141–1151. doi: 10.1016/0360-3016(89)90519-1. - DOI - PubMed

Publication types

LinkOut - more resources